Our Next Show: The Evolving Role of Proteasome Inhibitors in Today's Myeloma Therapies with Dr. Jacob Laubach, MD, MPP, Dana Farber, Friday, May 13 @ 11 am EST
Jacob Laubach, MD, is Clinical Director of the Dana Farber Cancer Institute's Multiple Myeloma Program as well as Senior Physician of Medicine at the Dana Farber Cancer Institute and Assistant Professor of Medicine of the Harvard Medical School. Additionally, he is Associate Physician in the Department of Medicine at Brigham and Women's Hospital. Dr. Laubach is a member of the American Society of Hematology abstract review committee and reviews journal articles in publications such as Blood, the British Journal of Haematology, Cancer, Leukemia, and the New England Journal of Medicine. Since joining the Dana Farber Cancer Institute faculty in 2008, he has dedicated his efforts to the study of new therapeutic agents for multiple myeloma and was heavily involved in the study of HDAC inhibitors and the development of monoclonal antibodies daratumumab and elotuzumab. Dr. Laubach teaches regularly on multiple myeloma for students and has lectured regularly on the topic.
Thanks to our episode sponsor, Takeda Oncology.